Author(s):
Piyushkumar M. Pargi, Bhargav M. Purohit, Lla N. Hadiyel, Tathagata Roy, Debraj Mukhopadhyay, Somsubhra Ghosh, Susanta Paul
Email(s):
troy@jisuniversity.ac.in
DOI:
10.5958/0974-360X.2020.00754.4 
Address:
Piyushkumar M. Pargi1, Bhargav M. Purohit2, Lla N. Hadiyel2, Tathagata Roy3*, Debraj Mukhopadhyay4, Somsubhra Ghosh5, Susanta Paul6
1Department of Pharmacology, Government Medical College Bhavnagar - 364001.
2Associate Professor, Department of Pharmacology,Government Medical College Bhavnagar - 364001.
3Assistant Professor, Department of Pharmaceutical Technology, JIS University, Kolkata - 700109.
4School of Allied Health Sciences, Delhi Pharmaceutical Sciences and Research University (DIPSRU), New Delhi.
5Assistant Professor, Department of Pharmaceutical Technolog, NSHM Knowledge Campus, Kolkata- Group of Institution, 124, B. L. Saha Road, Kolkata- 700053, W.B.
6Assistant Professor, Department of Pharmaceutical Technology , JIS University, Kolkata - 700109.
*Corresponding Author
Published In:
Volume - 13,
Issue - 9,
Year - 2020
ABSTRACT:
The prevalence of oral lichen planus (LP) in Indian population is 2.6% with more female predilection. LP is considered idiopathic but there are anecdotal reports of various medications like ß-blockers, nonsteroidal anti-inflammatory drugs (NSAIDs), methyldopa, penicillamine, quinidine, quinine and angiotensin-converting enzyme (ACE) inhibitors.Metoprolol is rarely being reported to cause oral lichen planus despite its common usage. A 25 years old female patient developed bilateral oral lichen planus after administration of metoprolol, which was given for treatment of postpartum dilated cardiac myopathy with atrial fibrillation. Diltiazem was prescribed in place of metoprolol and patient was improved. Increased awareness of prescribers, close monitoring with immediate withdrawal of the culprit drug can reduce the complexity of management that occur due to development of such adverse drug reaction.
Cite this article:
Piyushkumar M. Pargi, Bhargav M. Purohit, Lla N. Hadiyel, Tathagata Roy, Debraj Mukhopadhyay, Somsubhra Ghosh, Susanta Paul. Metoprolol Induced oral Lichen planus in An adult Female Patient – A Case Report. Research J. Pharm. and Tech 2020; 13(9):4274-4276. doi: 10.5958/0974-360X.2020.00754.4
Cite(Electronic):
Piyushkumar M. Pargi, Bhargav M. Purohit, Lla N. Hadiyel, Tathagata Roy, Debraj Mukhopadhyay, Somsubhra Ghosh, Susanta Paul. Metoprolol Induced oral Lichen planus in An adult Female Patient – A Case Report. Research J. Pharm. and Tech 2020; 13(9):4274-4276. doi: 10.5958/0974-360X.2020.00754.4 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2020-13-9-42
REFERENCES:
1. Shirasuna K. Oral lichen planus: Malignant potential and diagnosis. Oral Sci Int. 2014; 1;11(1):1–7.
2. Murti PR, Daftary DK, Bhonsle RB, Gupta PC, Mehta FS, Pindborg JJ. Malignant potential of oral lichen planus: observations in 722 patients from India. J Oral Pathol. 1986;15(2):71–7.
3. Mattsson U, Jontell M, Holmstrup P. Oral lichen planus and malignant transformation: is a recall of patients justified? Crit Rev Oral Biol Med Off Publ Am Assoc Oral Biol. 2002;13(5):390–6.
4. Sugerman PB, Savage NW. Oral lichen planus: causes, diagnosis and management. Aust Dent J. 2002 Dec;47(4):290–7.
5. Andreasen JO. Oral lichen planus. 1. A clinical evaluation of 115 cases. Oral Surg Oral Med Oral Pathol. 1968;25(1):31–42.
6. Carrozzo M, Thorpe R. Oral lichen planus: a review. Minerva Stomatol. 2009;58(10):519–37.
7. Roopashree MR, Gondhalekar RV, Shashikanth MC, George J, Thippeswamy SH, Shukla A. Pathogenesis of oral lichen planus--a review. J Oral Pathol Med Off PublIntAssoc Oral Pathol Am AcadOral Pathol. 2010;39(10):729–34.
8. Goldner JA. Metoprolol-induced visual hallucinations: a case series. J Med Case Reports. 2012; 15: 6:65.
9. WHOcausality_assessment.pdf [Internet]. [cited 2018 Nov 12]. Available from: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf
10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions.ClinPharmacolTher. 30(2):239–45.
11. Schumock GT, Thornton JP.Focusing on the preventability of adverse drug reactions.Hosp Pharm. 1992;27(6):538.
12. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49(9):2229–32.
13. Edwards PC, Kelsch R. Oral lichen planus: clinical presentation and management. J Can Dent Assoc. 2002;68(8):494–9.
14. Clayton R, Chaudhry S, Ali I, Cooper S, Hodgson T, Wojnarowska F. Mucosal (oral and vulval) lichen planus in women: are angiotensin-converting enzyme inhibitors protective, and beta-blockers and non-steroidal anti-inflammatory drugs associated with the condition? ClinExpDermatol. 2010;35(4):384–7.
15. Chen J, Ho BB. b-Adrenergic Receptor Activation Inhibits Keratinocyte Migration via a Cyclic Adenosine Monophosphate-independent Mechanism. J Invest Dermatol. 2002;119(6):8.
16. Manni M, Maestroni GJM. Sympathetic nervous modulation of the skin innate and adaptive immune response to peptidoglycan but not lipopolysaccharide: Involvement of β-adrenoceptors and relevance in inflammatory diseases. Brain Behav Immun. 2008;22(1):80–8.
17. Fessa C, Lim P, Kossard S, Richards S, Peñas PF. Lichen planus-like drug eruptions due to β-blockers: a case report and literature review. Am J ClinDermatol. 2012;13(6):417–21.
18. Sivamani RK, Lam ST, Isseroff RR.Beta Adrenergic Receptors in Keratinocytes.DermatolClin. 2007;25(4):643–53.
19. Varghese SS, George GB, Sarojini SB, Vinod S, Mathew P, Mathew DG, et al. Epidemiology of Oral Lichen Planus in a Cohort of South Indian Population: A Retrospective Study. J Cancer Prev. 2016;21(1):55–9.